{
    "clinical_study": {
        "@rank": "9818", 
        "arm_group": [
            {
                "arm_group_label": "Candemore tablet", 
                "arm_group_type": "Experimental", 
                "description": "Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks"
            }, 
            {
                "arm_group_label": "Cozzar tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare efficacy and safety of candesartan and losartan in\n      hypertension with heart failure."
        }, 
        "brief_title": "The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, open-label, phase 4 study. wash out periods need at least 14 days if\n      the patients take ARB or ACE inhibitor to control Blood pressure. Patients take Candemore or\n      Cozzar once a day during 16 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients who aged above 19 and below 75\n\n          -  Patients with 90~109mmHg average sitting DBP on baseline\n\n          -  NYHA class 2~4\n\n          -  Patients who agreement with written informed consent\n\n        Exclusion Criteria:\n\n          -  above 110mmHg sitting DBP and/or 180mmHg sitting SBP\n\n          -  Patients who have difference values that above 20mmHg sitting SBP or 10mmHg sitting\n             DBP in both arms on screening\n\n          -  Patients who have medical history that secondary hypertension or rule out secondary\n             hypertension\n\n          -  malignant hypertension\n\n          -  symptomatic postural hypotension\n\n          -  right heart failure due to pulmonary disease\n\n          -  etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766505", 
            "org_study_id": "m111HHF11F"
        }, 
        "intervention": [
            {
                "arm_group_label": "Candemore tablet", 
                "description": "Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.\ndosage is depends on the sitting blood pressure.", 
                "intervention_name": "Candemore tablet", 
                "intervention_type": "Drug", 
                "other_name": "Candemore tablet"
            }, 
            {
                "arm_group_label": "Cozzar tablet", 
                "description": "Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure", 
                "intervention_name": "Cozzar tablet", 
                "intervention_type": "Drug", 
                "other_name": "Cozzar tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Losartan", 
                "Candesartan", 
                "Candesartan cilexetil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "hypertension, heart failure, candesartan, losartan", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chonju", 
                        "country": "Korea, Republic of", 
                        "zip": "561-712"
                    }, 
                    "name": "Chunbuk National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chunju", 
                        "country": "Korea, Republic of", 
                        "zip": "560-750"
                    }, 
                    "name": "Presbyterian Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-723"
                    }, 
                    "name": "The catholic university of Korea, Daejeon st. Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "302-799"
                    }, 
                    "name": "Eulji University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "301-721"
                    }, 
                    "name": "Chungnam national university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejon", 
                        "country": "Korea, Republic of", 
                        "zip": "302-718"
                    }, 
                    "name": "Konyang university hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of", 
                        "zip": "501-757"
                    }, 
                    "name": "Chunnam National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of", 
                        "zip": "503-715"
                    }, 
                    "name": "Kwangju Christian Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suncheon", 
                        "country": "Korea, Republic of", 
                        "zip": "540-719"
                    }, 
                    "name": "ST.Carollo hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.", 
        "other_outcome": [
            {
                "measure": "rate of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "medication history", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Chonnam National University Hospital", 
            "last_name": "Myungho Jeong, phD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "change from baseline average sitting DBP(diastolic blood pressure)at 16 weeks", 
            "safety_issue": "No", 
            "time_frame": "baseline, 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change from baseline average sitting DBP(diastolic blood pressure)at 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 8 weeks"
            }, 
            {
                "measure": "change from baseline average sitting SBP(systolic blood pressure)at 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 8 weeks"
            }, 
            {
                "measure": "change from baseline average sitting SBP(systolic blood pressure)at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "description": "normalize means that sitting SBP and DBP is below 140mmHg and 90mmHg", 
                "measure": "ratio of normalize from baseline blood pressure at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "description": "response means that decrease in sitting DBP and SBP is above 10mmHg and 20mmHg", 
                "measure": "response ratio from baseline blood pressure at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "measure": "change from baseline LVEF(left ventricular ejection fraction at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "measure": "change from baseline LVEDD(left ventricular end-diastolic diameter)at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "measure": "change from baseline LV(left ventricular) mass at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }, 
            {
                "measure": "change from baseline PWV(pulse wave velocity) mass at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "baseline, 16 weeks"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "lack of the subjects"
    }
}